Drug Details

General Information of the Drug (ID: DR8953)
Name
Captopril
Synonyms
captopril; 62571-86-2; Capoten; L-Captopril; Lopirin; Captopryl; Cesplon; Captolane; Tensoprel; Acepress; Captoril; Dilabar; Garranil; Hypertil; Tenosbon; Alopresin; Acepril; Lopril; Captoprilum; Acediur; Aceplus; (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid; Tensobon; Apopril; Captoprilum [INN-Latin]; SQ 14225; SQ-14225; D-2-Methyl-3-mercaptopropanoyl-L-proline; D-3-Mercapto-2-methylpropanoyl-L-proline; SQ 14,225; 1-((2S)-3-Mercapto-2-methylpropionyl)-L-proline; SA 333; D-3-Mercapto-2-methylpropionylproline; 1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline; (2S)-1-(3-Mercapto-2-methylpropionyl)-L-proline; UNII-9G64RSX1XD; Hipertil; CHEBI:3380; L-Proline, 1-[(2S)-3-mercapto-2-methyl-1-oxopropyl]-; L-Proline, 1-(3-mercapto-2-methyl-1-oxopropyl)-, (S)-; 9G64RSX1XD; CHEMBL1560; 1-[(2S)-3-Mercapto-2-methyl-1-oxopropyl]-L-proline; MLS000069484; Asisten; Isopresol; (-)-Captopril; C9H15NO3S; [2S]-1-[3-Mercapto-2-methylpropionyl]-L-proline; 1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; Captopril, 98%; MFCD00168073; (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; NCGC00023654-04; SMR000059061; Lopirin [Switzerland]; (S)-1-((S)-3-mercapto-2-methylpropanoyl)pyrrolidine-2-carboxylic acid; 1-Pyrrolidinecarboxylic acid, 1-(D-3-mercapto-2-methyl-1-propionyl)-, L-(S,S)-; DSSTox_CID_17197; DSSTox_RID_79306; DSSTox_GSID_37197; L-Proline, 1-((2S)-3-mercapto-2-methyl-1-oxopropyl)-; Novocaptopril; Captril; Farcopril; Hypopress; Tensiomin; Zapto; Captopril (Capoten); Capozide (Salt/Mix); 3-Mercapto-2-methylpropionyl-proline; X8Z; Apopril (TN); Capoten (TN); HSDB 6527; 1-[(2s)-3-mercapto-2-methylpropionyl]-l-proline; SR-01000075603; EINECS 263-607-1; component of Captea (Salt/Mix); component of Acezide (Salt/Mix); component of Ecazide (Salt/Mix); 1-(D-3-Mercapto-2-methyl-1-oxopropyl)-L-proline (S,S); (2S)-1-((2S)-2-methyl-3-sulfanylpropanoyl)pyrrolidine-2-carboxylic acid; C09AA01; Captopril,(S); Prestwick_103; Captopril [USAN:USP:INN:BAN:JAN]; SQ14534; SCHEMBL4; Spectrum_000688; Opera_ID_1041; Prestwick3_000019; Spectrum2_001211; Spectrum3_001388; Spectrum4_000811; Spectrum5_001587; Lopac-C-4042; 1-((2S)-2-Methyl-3-sulfanylpropanoyl)-L-proline #; Epitope ID:114065; UPCMLD-DP003; C 4042; Lopac0_000302; N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline; BSPBio_000057; BSPBio_002976; KBioGR_001321; KBioSS_001168; MLS001076488; DivK1c_000208; SPECTRUM1500682; SPBio_001022; Captopril (JP17/USP/INN); (S)-1-(3-Mercapto-2-methyl-1-oxo-propyl)-L-proline; BPBio1_000063; GTPL5158; DTXSID1037197; UPCMLD-DP003:001; BDBM21642; HMS500K10; KBio1_000208; KBio2_001168; KBio2_003736; KBio2_006304; KBio3_002196; ZINC57001; 1j37; NINDS_000208; HMS1921C12; HMS2089P19; HMS2092I12; HMS2095C19; HMS2233I04; HMS3259G10; HMS3260N06; HMS3712C19; Pharmakon1600-01500682; HY-B0368; Tox21_110890; Tox21_500302; BBL033600; CCG-39104; EI-213; KM0635; NSC757419; s2051; SA-333; SBB017523; STK802012; AKOS005622581; Captopril, >=98% (HPLC), powder; Tox21_110890_1; AB04252; BCP9000485; CS-2425; DB01197; KS-5025; LP00302; MCULE-1716939647; NC00554; NSC 757419; NSC-757419; SDCCGSBI-0050290.P006; IDI1_000208; SMP1_000056; NCGC00015235-01; NCGC00015235-02; NCGC00023654-03; NCGC00023654-05; NCGC00023654-06; NCGC00023654-07; NCGC00023654-08; NCGC00023654-09; NCGC00023654-10; NCGC00023654-11; NCGC00023654-13; NCGC00023654-25; NCGC00260987-01; AC-12047; AC-32120; ST079562; SBI-0050290.P004; AB0007072; Captopril, meets USP testing specifications; SQ -14225; EU-0100302; ((S)-3-mercapto-2-methylpropanoyl)-L-proline; BIM-0050290.0001; C06867; D00251; J10167; 54254-EP2269989A1; 54254-EP2270011A1; 54254-EP2272841A1; 54254-EP2277879A1; 54254-EP2287165A2; 54254-EP2287166A2; 54254-EP2292620A2; 54254-EP2295406A1; 54254-EP2298742A1; 54254-EP2298772A1; 54254-EP2298776A1; 54254-EP2298779A1; 54254-EP2301923A1; 54254-EP2301931A1; 54254-EP2301936A1; 54254-EP2305219A1; 54254-EP2305648A1; 54254-EP2308562A2; 54254-EP2308839A1; AB00052156-16; AB00052156_17; AB00052156_18; 571C862; Q421119; SR-01000000039; 1-[(2S)-3-Mercapto-2-methylpropionyl]- L-proline; SR-01000000039-2; SR-01000075603-1; SR-01000075603-3; 1-[(S)-3-mercapto-2-methyl-1-oxopropyl]-L-proline; BRD-K54529596-001-04-0; BRD-K54529596-001-15-6; Captopril, British Pharmacopoeia (BP) Reference Standard; Z2786051697; Captopril, European Pharmacopoeia (EP) Reference Standard; Captopril, United States Pharmacopeia (USP) Reference Standard; Captopril, Pharmaceutical Secondary Standard; Certified Reference Material; L-?Proline, 1-?[(2S)?-?3-?mercapto-?2-?methyl-?1-?oxopropyl]?-; Captopril for system suitability, European Pharmacopoeia (EP) Reference Standard
    Click to Show/Hide
Molecular Type
Small molecule
Disease Hypertension [ICD-11: BA00] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability
Bioavailability
69% of drug becomes completely available to its intended biological destination(s)
Clearance
The drug present in the plasma can be removed from the body at the rate of 12 mL/min/kg
Elimination
38% of drug is excreted from urine in the unchanged form
Half-life
The concentration or amount of drug in body reduced by one-half in 2 hours
Metabolism
The drug is metabolized via the hepatic
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 19.7235 micromolar/kg/day
Unbound Fraction
The unbound fraction of drug in plasma is 0.73%
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.75 L/kg
Water Solubility
The ability of drug to dissolve in water is measured as 160 mg/mL
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C9H15NO3S
PubChem CID
44093
Canonical SMILES
CC(CS)C(=O)N1CCCC1C(=O)O
InChI
1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1
InChIKey
FAKRSMQSSFJEIM-RQJHMYQMSA-N
CAS Number
CAS 62571-86-2
ChEBI ID
CHEBI:3380
TTD Drug ID
D0I0EG
DrugBank ID
DB01197
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Apocynin      Picrorhiza kurrooa     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model A 5/6 nephrectomy mouse model of CDK was used in this study.
                    Experimental
                    Result(s)		 Apocynin in conjunction with a coadjuvant for modulating blood pressure may be useful for controlling the progression of CRF.
Target and Pathway
Target(s) Angiotensin-converting enzyme 1 (ACE1)  Molecule Info  [3]
KEGG Pathway Renin-angiotensin system Click to Show/Hide
2 Chagas disease (American trypanosomiasis)
3 Hypertrophic cardiomyopathy (HCM)
Pathwhiz Pathway Angiotensin Metabolism Click to Show/Hide
Reactome Metabolism of Angiotensinogen to Angiotensins Click to Show/Hide
WikiPathways ACE Inhibitor Pathway Click to Show/Hide
2 Metabolism of Angiotensinogen to Angiotensins
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5158).
Reference 2 Apocynin combined with drugs as coadjuvant could be employed to prevent and/or treat the chronic kidney disease. Ren Fail. 2018 Nov;40(1):92-98.
Reference 3 Using ACE inhibitors appropriately. Am Fam Physician. 2002 Aug 1;66(3):461-8.
 Download Picture         KEGG Link